布里脏病的治疗:一篇文献综述
Homare Shimohata1,2, Marina Yamashita1, Kota Yamada2
1Department of Nephrology, Tokyo Medical University Ibaraki Medical Center, Ami 300-0395, Ibaraki, Japan.
Medicina (Kaunas, Lithuania)
|August 26, 2023
概括
包括酶替代和陪伴疗法在内的法布里病治疗改善功能,减少法布里脏病患者的蛋白尿症. 辅助疗法对于管理这种遗传性疾病也至关重要.
科学领域:
- 遗传学和罕见疾病.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 费布里病是一种X链 lysosomal 储存障碍,由α-galactosidase A 缺乏引起.
- 这种缺陷导致全球酸胺的积累,主要影响脏 (法布里脏病) 和心脏.
- 费布里脏病对发病率和死亡率做出了重大贡献,这强调了需要有效治疗的必要性.
研究的目的:
- 审查目前针对法布里脏病的治疗方法的疗效.
- 评估治疗对功能,蛋白尿和病理学的影响.
- 突出辅助疗法在管理法布里病中的作用.
主要方法:
- 关于酶替代疗法 (agalsidase alfa,agalsidase beta,生物类似药) 和药理性陪伴疗法 (migalastat) 的现有文献的综述.
- 对评估接受这些治疗的患者功能,蛋白尿水平和病理发现的研究分析.
- 对辅助治疗策略的讨论.
主要成果:
- 酶替代疗法和米加拉斯塔特在改善功能和减少法布里脏病中的蛋白尿症方面表现出有效性.
- 这些治疗可以改善病理发现.
- 辅助疗法在优化Fabry脏病患者的治疗结果方面发挥着重要作用.
结论:
- 现有的治疗方法为法布里脏病患者提供了显著的好处.
- 监测功能,蛋白尿和病理是评估治疗有效性的必要条件.
- 包括辅助疗法在内的综合管理方法对于改善法布里病的长期结果至关重要.
相关概念视频
01:26Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
203
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
203
01:28Chronic Kidney Disease III: Interprofessional Care
42
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
42
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:24Nephrotic Syndrome I : Introduction
9
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
9
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201